Bio-Techne stock has a November 4, 2026 reporting date
Published on 10/17/2026 at 18:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and valuation
- The next quarterly report is scheduled for November 4, 2026.
- Next-quarter revenue is estimated at USD 292.61 million.
- Bio-Techne stock last stood at EUR 64.57 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.
- Bio-Techne trades at a P/E ratio of 62.56.
Bio-Techne (ISIN US09073M1045) has its next quarterly reporting date scheduled for November 4, 2026, according to MarketBeat. The company stock last stood at EUR 64.57 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.
Revenue expectations set the next marker
MarketBeat lists consensus revenue of USD 292.61 million for the first quarter of fiscal 2027, against USD 286.56 million in the year-earlier quarter. The same estimate puts earnings per share at USD 0.4433, compared with USD 0.42 a year earlier. The reporting date is an estimate rather than a company-confirmed calendar entry, and the source identifies the conference call for 9:00 a.m. ET.
Margins remain central to the picture
Bio-Techne's latest investor-relations page identifies fiscal year 2026 as the most recent full-year reporting period. Revenue was USD 321.2 million, adjusted gross margin was 69.2 percent, adjusted operating margin was 32.2 percent and adjusted earnings per share was USD 0.52, according to Bio-Techne. These figures give investors a direct benchmark for the next report.
On October 8, 2026, Bio-Techne said it was expanding its global GMP manufacturing network with a new Bristol facility, a dated company update listed on its investor-relations page. The operational focus matters because the company supplies reagents, analytical instruments and precision diagnostics to research and clinical customers.
Price position and valuation
The finance snapshot places Bio-Techne's Nasdaq quote at USD 72.57 on October 16, 2026 at 4:00 p.m. ET. Its 52-week range was USD 43.20 to USD 72.69, while market capitalization was USD 11.4 billion and the P/E ratio was 62.56. The 52-week high therefore stood USD 0.12 above that Nasdaq quote.
Comparison with peers
Bio-Techne (Nasdaq, USD): P/E 62.56, market capitalization USD 11.4 billion
Danaher (NYSE, USD): minus 1.06 percent, P/E 40.68, market capitalization USD 161.0 billion
Agilent Technologies (NYSE, USD): minus 1.47 percent, P/E 34.05, market capitalization USD 48.8 billion
What comes next for the stock
The November 4, 2026 reporting date puts the next comparison point on revenue, earnings per share and margins. The market will also have to weigh the USD 292.61 million consensus revenue estimate against the USD 321.2 million fiscal 2026 figure, which covers a different reporting period.
Price and market context
Bio-Techne last stood at EUR 64.57 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Bio-Techne stock.
Bio-Techne market data
- Company: Bio-Techne Corporation
- ISIN: US09073M1045
- Ticker: TECH
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 16, 2026, 11:00 p.m. CEST): EUR 64.57
- Market capitalization: USD 11.4 billion (as of October 16, 2026)
- 52-week range: USD 43.20-USD 72.69 (as of October 16, 2026)
- Sector / Industry: Health care / Life sciences tools and services
- Index membership: S&P 500
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
